Treatment with XPro1595 of the ‘ARIA-at-risk’ Population of MINDFuL: Subpopulation Results of the 6-month Phase 2 Trial Targeting Neuroinflammation in Early Alzheimer’s Disease

Pharmacokinetics, Pharmacodynamics, and Safety of IVL3003: A Novel Long-acting Injectable Acetylcholinesterase Inhibitor Compared with Oral Donepezil